Posts by WGNV

Accelerating research and development of new vaccines against tuberculosis: 5-year progress on the global roadmap. van Riet E, Corleis B, Giersing BK, Hatherill M, Burhan E, Jassat W, White RG, Lewinsohn D, Cobelens F. Lancet Infect Dis. 2026 Jul;26(7):e289-e301. doi: 10.1016/S1473-3099(26)00019-8. Epub 2026 Mar 18. Applications of humanized mice in Mycobacterium tuberculosisinfections (Review). Han B, Liu…

The host immune response to Mycobacterium tuberculosis determining protection or disease progression. Nat Immunol. 2026 Jun;27(6):1104-1118. doi: 10.1038/s41590-026-02529-z. Epub 2026 May 18. A proteome-wide atlas of humoral immunity to Mycobacterium tuberculosisacross the spectrum of disease. Khan MZ, Irvine EB, Cizmeci D, Davies LRL, Randall AZ, Pablo J, Vidal SJ, Lasrado N, Darrah PA, Hsiao JC, Mann…

Preparing for Tuberculosis Vaccine M72/AS01EImplementation: A Global Demand Forecast and Key Influential Factors. Kallenberg J, Milea D, Breuer T, Philippot A. Infect Dis Ther. 2026 May;15(5):1263-1279. doi: 10.1007/s40121-026-01319-2. Epub 2026 Feb 25. Enhanced tuberculosis control via leveraging dendritic cell-mediated Th1 responses in preventive and immunotherapeutic vaccine strategies. Kim H, Kim JS, Kwon KW, Kim WS,…

Interferon-gamma release assay positivity in populations at high risk of TB infection. Dagnew AF, Han LL, Cinar A, Gaikwad D, Garcia-Basteiro AL, Gler MT, Hadinegoro SR, Hanekom WA, Lama JR, Muyoyeta M, Musala S, Nduba V, Rolla VC, Roy T, Sutherland JS. Viegas S, Wajja A, Walker TM, Noble R, Schlehuber L, Sunshine, Schmidt AC.…

Leveraging Mycobacterium tuberculosis Rv1507A Protein for Improved Immunogenicity in Mycobacterium bovis BCG Vaccine. Naqvi N, Alam A, Shariq M, Ahuja Y, Mitra DK, Hasnain SE, Ehtesham NZ. Immunology. 2026 Mar;177(3):526-539. doi: 10.1111/imm.70063. Epub 2025 Nov 8. Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials. Seshadri C, Flynn JL, Maiello P, Schnappinger D,…